The Technical Analyst
Sinovac Biotech Ltd. [SVA]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Sinovac Biotech Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $6.47
/ 4 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 464.06 mill |
| EPS: | 0.971 |
| P/E: | 6.66 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 71.72 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2023-08-14 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | n/a | n/a | n/a | n/a | |
| Asset | n/a | n/a | n/a | n/a | n/a | |
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 6.66 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 6.66 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 6.47 - 6.47 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2003-11-04 | Ifg Investments Services Inc | Sell | 6 027 870 | Common Shares |
| 2003-09-24 | Ifg Investments Services Inc | Sell | 6 027 870 | Common Shares |
| 2003-09-24 | Weidong Yin | Sell | 0 | Common Shares |
| 2003-09-24 | Wang Lily | Sell | 0 | Common Shares |
| 2003-09-24 | Bowering Terry G | Sell | 500 000 | Common Shares |
| INSIDER POWER |
|---|
| 0.00 |
| Last 5 transactions |
| Buy: 0 | Sell: 12 555 740 |
Forecast:
01:40 - $6.47
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.47 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SVA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SVA
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Latest Press Releases
2024-02-21 02:56:00 - Press Release
Sinovac Amends Shareholder Rights Plan
Beijing--(business wire)--sinovac biotech ltd. (“sinovac” or the “company”) (nasdaq: sva), a leading provider of biopharmaceutical products in china, today announced that its board of directors has amended its shareholder rights plan. the amendment extends the expiration date of the plan from february 22, 2024 to february 22, 2025. about sinovac sinovac biotech ltd. (sinovac) is a china-based biopharmaceutical company that focuses on the r&d, manufacturing, and commercialization of biomedic.
2024-01-18 07:00:00 - Press Release
Sinovac Board Of Directors Unanimously Rejects An Unsolicited Partial Tender Offer
Beijing--(business wire)--sinovac biotech ltd. (nasdaq: sva) (“sinovac” or the “company”), a leading provider of biopharmaceutical products in china, announced today that its board of directors (the “board of directors”) unanimously determined that the partial tender offer (the “tender offer”) by alternative liquidity index lp (“alternative liquidity”) to acquire up to 10,000,000 common shares of sinovac (the “shares”) for $0.03 per share in cash (the “offer price”) is not advisable and is not.
2023-09-11 05:55:00 - Press Release
Sinovac Reports On The Clinical Trial Progress Of Its Anti-covid-19 Antibody Sa55 Injection
Beijing--(business wire)--sinovac biotech ltd. (“sinovac” or the “company”) (nasdaq: sva), a leading provider of biopharmaceutical products in china, announced that the company has completed the phase i clinical trial for its broad-spectrum neutralizing antibody product, the anti-covid-19 antibody sa55 injection (“sa55 injection”) in beijing and has entered the phase ii clinical trial in shanghai after successfully enrolling its first participant recently. sinovac's sa55 injection, which is int.
2023-09-05 04:12:00 - Press Release
Sinovac Board Of Directors Unanimously Rejects An Unsolicited Partial Tender Offer
Beijing--(business wire)--sinovac biotech ltd. (nasdaq: sva) (“sinovac” or the “company”), a leading provider of biopharmaceutical products in china, announced today that its board of directors (the “board of directors”) unanimously determined that the partial tender offer (the “tender offer”) by alternative liquidity index lp (“alternative liquidity”) to acquire up to 10,000,000 common shares of sinovac (the “shares”) for $0.03 per share in cash (the “offer price”) is not advisable and is not.
2023-08-29 03:07:00 - Press Release
Sinovac Confirms Receipt Of An Unsolicited Partial Tender Offer
Beijing--(business wire)--sinovac biotech ltd. (nasdaq: sva) (“sinovac” or the “company”), a leading provider of biopharmaceutical products in china, confirmed today that it is aware of an unsolicited partial tender offer from alternative liquidity index lp to purchase up to a maximum of 10,000,000 shares of the company, representing approximately 10.05% of the company's outstanding shares, for $0.03 per share in cash. sinovac's board of directors intends to evaluate the terms of the tender off.
Latest News
2022-01-03 07:23:08 - Benzinga
Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron: Reuters
China-based Sinovac Biotech Ltd's (NASDAQ: SVA) two-dose COVID-19 vaccine followed by a booster Pfizer Inc (NYSE: PFE) -BioNTech SE (NASDAQ: BNTX) shot showed a lower immune response against the Omicron variant compared with other strains, according to a study. The study was conducted by researchers from Yale University, the Dominican Republic's Ministry of Health, and other institutions.
2021-09-24 09:16:23 - Benzinga
Sinovac's COVID-19 Vaccine Shows Efficacy, But Lags Rivals In Malaysian Study: Reuters
According to a real-world study from Malaysia, Sinovac Biotech Ltd's (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, showed effectiveness against serious illness. However, shots from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and AstraZeneca plc (NASDAQ: AZN) demonstrated better protection rates, reported Reuters.
2021-09-09 06:00:00 - Business Wire
New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced a paper, titled “A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2,” is available on medRxiv. The findings suggest a third dose of CoronaVac® can induce a better neutralization breadth to variants of concern (“VOCs”), including the Delta variant, a rapid immunologic
2021-07-12 05:40:00 - Business Wire
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it had signed an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi), which is on behalf of COVAX Facility, to provide up to 380 million doses of inactivated COVID-19 vaccine, CoronaVac®for distribution through the COVAX Facility. According to the APA, SINOVAC will supply 50 million doses of CoronaVac® by t
2021-06-30 06:30:00 - Business Wire
The Lancet Infectious Diseases Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced The Lancet Infectious Diseases published results from the Phase I/II clinical trials of an inactivated COVID-19 vaccine developed by SINOVAC, also known as CoronaVac®, in healthy children and adolescents aged 3-17 in China. The double-blind, randomized, placebo-controlled study evaluated the safety, tolerability and immunogenicity of Cor
2021-06-18 11:23:00 - Seeking Alpha
Pandemic Accelerates China's Drive Into mRNA Treatments
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese companies into mRNA vaccines and treatments.
2021-05-11 18:36:30 - Bloomberg Markets and Finance
Sinovac CEO Yin Discusses CoronaVac's Efficacy
May.11 -- Sinovac Biotech Ltd.'s vaccine is wiping out Covid-19 among health workers in Indonesia, an encouraging sign for the dozens of developing countries reliant on the controversial Chinese shot, which performed far worse than western vaccines in clinical trials.
2021-05-10 02:00:00 - Seeking Alpha
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian vaccine, Sputnik V.
2021-04-22 18:51:00 - Business Wire
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Summary Sales for the fourth quarter of 2020 were $327.5 million,
2021-04-01 23:30:00 - Business Wire
Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial production. Including this new production line, Sinovac's annual capacity of CoronaVac® has reached 2 billion doses. At this time, over 200 million doses of CoronaVac have been delivered to over 20 countries, including China. I